Prevalence and Influence Factors for Non-Alcoholic Fatty Liver Disease in Long-Term Hospitalized Patients with Schizophrenia: A Cross-Sectional Retrospective Study

被引:3
作者
Li, Xuelong [1 ,2 ,3 ]
Gao, Yakun [4 ]
Wang, Yongmei [2 ,3 ,5 ]
Wang, Ying [2 ,3 ,5 ]
Wu, Qing [1 ,2 ,3 ,5 ]
机构
[1] Anhui Med Univ, Sch Mental Hlth & Psychol Sci, Hefei, Peoples R China
[2] Anhui Med Univ, Affiliated Psychol Hosp, Dept Psychiat, 316 Huangshan Rd, Hefei 230000, Peoples R China
[3] Anhui Mental Hlth Ctr, Hefei, Peoples R China
[4] Weifang Med Coll, Affiliated Hosp, Weifang, Peoples R China
[5] Hefei Fourth Peoples Hosp, Hefei, Peoples R China
关键词
schizophrenia; non-alcoholic fatty liver disease; prevalence; influence factors; long-term hospitalization; PSYCHIATRIC-PATIENTS; ANTIPSYCHOTIC-DRUGS; RISK; ASSOCIATION; MANAGEMENT; PREDICT; CYCLE; ACID;
D O I
10.2147/NDT.S398385
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Long-term hospitalized patients with schizophrenia (SCZ) are vulnerable to physical illness, leading to impaired life expectancy and treatment outcomes. There are few studies on the influence of non-alcoholic fatty liver disease (NAFLD) in long-term hospitalized patients. This study aimed to investigate the prevalence of and influence factors for NAFLD in hospitalized patients with SCZ.Patients and Methods: This cross-sectional retrospective study included 310 patients who had experienced long-term hospitaliza-tion for SCZ. NAFLD was diagnosed based on the results of abdominal ultrasonography. The T-test, Mann-Whitney U-test, correlation analysis, and logistic regression analysis were used to determine the influence factors for NAFLD.Results: Among the 310 patients who had experienced long-term hospitalization for SCZ, the prevalence of NAFLD was 54.84%. Antipsychotic polypharmacy (APP), body mass index (BMI), hypertension, diabetes, total cholesterol (TC), apolipoprotein B (ApoB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglycerides (TG), uric acid, blood glucose, gamma-glutamyl transpeptidase (GGT), high-density lipoprotein, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio significantly differed between the NAFLD and non-NAFLD groups (all P<0.05). Hypertension, diabetes, APP, BMI, TG, TC, AST, ApoB, ALT, and GGT were positively correlated with NAFLD (all P<0.05). The results of the logistic regression analysis indicated that APP, diabetes, BMI, ALT, and ApoB were the influence factors for NAFLD in patients with SCZ.Conclusion: Our results suggest a high prevalence of NAFLD among patients hospitalized long-term due to severe SCZ symptoms. Moreover, a history of diabetes, APP, overweight/obese status, and increased levels of ALT and ApoB were identified as negative factors for NAFLD in these patients. These findings may provide a theoretical basis for the prevention and treatment of NAFLD in patients with SCZ and contribute to the development of novel targeted treatments.
引用
收藏
页码:379 / 389
页数:11
相关论文
共 57 条
  • [1] Hepatic steatosis in patients with schizophrenia: a clinical cross-sectional study
    Aaroe, Anna Sofie Kaestel
    Odgaard Maeng, Katrine
    Leifsdottir Jacobsen, Ragnhild
    Eggert Jensen, Svend
    Graff, Claus
    Polcwiartek, Christoffer
    Bolvig Mark, Esben
    Dalsgaard, Anja Borgen
    Tranekaer Hostrup, Camilla
    Veiss-Pedersen, Pernille
    Frokjaer, Jens Brondum
    Aagaard, Jorgen
    Nielsen, Rene Ernst
    [J]. NORDIC JOURNAL OF PSYCHIATRY, 2022, 76 (02) : 114 - 119
  • [2] Metabolic Syndrome and Cognitive Functions in Schizophrenia-Implementation of Dietary Intervention
    Adamowicz, Katarzyna
    Mazur, Aleksandra
    Mak, Monika
    Samochowiec, Jerzy
    Kucharska-Mazur, Jolanta
    [J]. FRONTIERS IN PSYCHIATRY, 2020, 11
  • [3] Partial-volume modeling reveals reduced gray matter in specific thalamic nuclei early in the time course of psychosis and chronic schizophrenia
    Aleman-Gomez, Yasser
    Najdenovska, Elena
    Roine, Timo
    Fartaria, Mario Joao
    Canales-Rodriguez, Erick J.
    Rovo, Zita
    Hagmann, Patric
    Conus, Philippe
    Do, Kim Q.
    Klauser, Paul
    Steullet, Pascal
    Baumann, Philipp S.
    Cuadra, Meritxell Bach
    [J]. HUMAN BRAIN MAPPING, 2020, 41 (14) : 4041 - 4061
  • [4] Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia
    Bolstad, Albert
    Andreassen, Ole A.
    Rossberg, Jan I.
    Agartz, Ingrid
    Melle, Ingrid
    Tanum, Lars
    [J]. BMC PSYCHIATRY, 2011, 11
  • [5] NAFLD: A multisystem disease
    Byrne, Christopher D.
    Targher, Giovanni
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S47 - S64
  • [6] Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro
    Canfran-Duque, Alberto
    Casado, Maria E.
    Pastor, Oscar
    Sanchez-Wandelmer, Jana
    de la Pena, Gema
    Lerma, Milagros
    Mariscal, Paloma
    Bracher, Franz
    Lasuncion, Miguel A.
    Busto, Rebeca
    [J]. JOURNAL OF LIPID RESEARCH, 2013, 54 (02) : 310 - 324
  • [7] Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits
    Centorrino, F
    Goren, JL
    Hennen, J
    Salvatore, P
    Kelleher, JP
    Baldessarini, RJ
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (04) : 700 - 706
  • [8] The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
    Chalasani, Naga
    Younossi, Zobair
    Lavine, Joel E.
    Charlton, Michael
    Cusi, Kenneth
    Rinella, Mary
    Harrison, Stephen A.
    Brunt, Elizabeth M.
    Sanyal, Arun J.
    [J]. HEPATOLOGY, 2018, 67 (01) : 328 - 357
  • [9] The Economic Burden of Schizophrenia in the United States in 2013
    Cloutier, Martin
    Aigbogun, Myrlene Sanon
    Guerin, Annie
    Nitulescu, Roy
    Ramanakumar, Agnihotram V.
    Kamat, Siddhesh A.
    DeLucia, Michael
    Duffy, Ruth
    Legacy, Susan N.
    Henderson, Crystal
    Francois, Clement
    Wu, Eric
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 (06) : 764 - +
  • [10] Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
    Di Lorenzo, Rosaria
    Ferri, Paola
    Cameli, Michela
    Rovesti, Sergio
    Piemonte, Chiara
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 183 - 198